For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on February 14th, 2024 | 07:00 CET
Plug Power, Bayer, Defense Metals: Shares in panic mode
Is everything not so bad at Plug Power, after all? In January, the hydrogen specialist triggered panic among investors with an announced capital increase. Now, the CEO is suddenly rowing back. So, should one buy the stock now? One analyst advises caution. Bayer shareholders are also in panic mode. The downward trend of the share simply cannot find a bottom. Even at this level, analysts are cautious. Defense Metals, on the other hand, is benefiting from panic - because this concerns the supply of rare earths. The dependence on China is enormous. Defense Metals aims to change this with its rare earth project in Canada. The Company CEO expressed confidence in an interview, stating that an important agreement has been reached with the local population, and important dates are on the horizon.
ReadCommented by Fabian Lorenz on February 7th, 2024 | 07:30 CET
BASF shares on the upswing, BioNTech sees breakthrough in cancer, and Defence Therapeutics benefits from study
Can BASF shareholders look forward to better times? One analyst is certainly hopeful. He believes that the chemical industry will recover in 2024. However, the price target gives pause for thought. The development of cervical cancer is also concerning. According to a new study, the number of cases has risen sharply in recent years, and with it, HPV infections. Accordingly, more HPV vaccines are urgently needed. The market volume is expected to more than double to over USD 15 billion in just a few years. Defence Therapeutics aims to become a profiteer. The biotech company is fighting cancer with its Accum™ platform. BioNTech CEO Ugur Sahin also believes that humanity will get cancer under control, thanks in part to artificial intelligence. The Company is currently working on 30 cancer therapies. Is it a good time to invest now?
ReadCommented by Fabian Lorenz on February 5th, 2024 | 07:45 CET
Is Bayer's share price about to jump? BYD off to a positive start! Manuka Resources with a billion-dollar opportunity!
Are Bayer shares on the verge of a price surge? According to analysts at Bernstein, the chemical company is significantly undervalued. Where does the optimism come from? Could there be a change in the Aspirin logo for Bayer in the near future? Chart-wise, the share is heavily battered. The chart for BYD also speaks a clear language. The electric vehicle manufacturer has reported a good start to 2024, while Manuka Resources' VTM iron sand project in New Zealand is generating share price fantasy. There is movement in the project, and following the capital increase, there is now an entry opportunity. Is the revaluation coming soon? The potential is in the billions.
ReadCommented by Fabian Lorenz on February 1st, 2024 | 07:30 CET
Top news: Plug Power, TUI, Prospera Energy
Should one buy Plug Power shares anti-cyclically now? Following the slump in the share price and the announced capital increase, more and more analysts are switching towards the bearish camp regarding the hydrogen pioneer. Has the bottom been reached? Prospera Energy shares have upside potential. The Canadian oil producer has met its targets for 2023, production is expected to increase significantly again in 2024, and the oil price is on the rise again. The share is, therefore, ripe for a turnaround. The TUI share has achieved this in the last few months of 2023. The share is currently consolidating. TUI is poised for a positive travel season in 2024 and aims to become more environmentally friendly.
ReadCommented by Fabian Lorenz on January 31st, 2024 | 07:30 CET
BYD disappoints! Siemens Energy share gives hope! The cash register is ringing at Klimat X Developments!
The preliminary figures did not generate any positive impetus - BYD shares continued to fall. Profits increased significantly, but analysts had expected more. A trend in the fourth quarter is also ringing alarm bells. Siemens Energy surprised positively last week with preliminary figures. Analysts have since had their say, and the share price targets diverge widely. Will the forecast be raised, or was Q1 a positive blip? Tesla has shown in recent years that one can earn a lot of money with CO2 certificates. Klimat X Developments has fully focused on this business model. In 2023, the reference project was driven forward, and another milestone payment was received. When will the share take off?
ReadCommented by Fabian Lorenz on January 26th, 2024 | 07:00 CET
Drumbeats and Buy recommendations: Siemens Energy, SAP, Cardiol Therapeutics
Analysts at First Berlin see over 200% upside potential for the Cardiol Therapeutics share. The biotech pearl is solidly financed to implement its development pipeline. Positive Phase II data and FDA approval for a Phase III trial are expected in the second quarter of 2024, which should drive the share price. Yesterday's top performers included the shares of Siemens Energy and SAP. At Siemens Energy, the situation at subsidiary Gamesa does not appear to be as catastrophic as feared. SAP is fully committed to the Cloud and AI. Shareholders do not seem bothered by the additional costs for the transformation in 2024; instead, they are celebrating future growth opportunities.
ReadCommented by Fabian Lorenz on January 24th, 2024 | 07:45 CET
More than 100% upside potential - Buy recommendations for BASF, Evotec and Saturn Oil + Gas
After the price slide of recent weeks, Evotec shares appear to be ripe for a countermovement. In a conference call, the Company attempted to provide clarification and seems to have convinced analysts. Expert opinions on BASF are divided. Has the bottom been reached after the preliminary figures? At least the dividend yield of 8% is attractive. Investors are also anticipating a high dividend from Saturn Oil & Gas soon. Analysts see more than 100% upside potential in the shares of the junior oil producer. The valuation is significantly lower than the peer group. The Canadian company will significantly reduce its debt in the current year, making the share increasingly attractive in terms of free cash flow and enterprise value. The latest drilling program has also produced strong results.
ReadCommented by Fabian Lorenz on January 18th, 2024 | 08:30 CET
Morphosys on the verge of a short squeeze? Evotec share drops like a stone! Almonty Industries is exciting!
Share price disaster at Evotec. The shares of the German biotech company are falling like a stone in 2024 and have already lost over 30% of their value in just a few trading days. This results from the CEO's surprising resignation and delayed reports of insider transactions. "Manager-Magazin" added fuel to the fire with an article. Morphosys, on the other hand, is taking off. The blood cancer drug Pelabresib is causing speculation and price swings. Could there even be a short squeeze? The Almonty Industries share is also exciting at the moment. The shares of the raw materials company, which focuses on tungsten, appear to have bottomed out and are starting an upward trend. Operationally, Almonty is facing exciting times. Analysts expect the tungsten producer to more than triple its turnover between 2023 and 2025. Given the expected profit in the coming year, the share is anything but expensive.
ReadCommented by Fabian Lorenz on January 17th, 2024 | 07:00 CET
Disaster at Plug Power! Opportunities with Thyssenkrupp Nucera and First Hydrogen shares!
The share price horror at hydrogen pioneers Nel and Plug Power continues in the new year. Yesterday alone, Plug Power's share price fell by more than 6% and has lost almost 30% of its value in just a few days of trading. Nel does not fare much better. Does this mean the comeback of hydrogen shares will fail in 2024? Investors should take a closer look at Plug Power; after all, the management itself has announced that it could run out of money. In terms of valuation and operational development, the two newcomers, First Hydrogen and Thyssekrupp Nucera, appear to be more attractive than the top dogs. Experts believe that First Hydrogen's shares, with their current market capitalization of CAD 80 million and further solid development in 2023, are currently on a special offer. And with Thyssenkrupp Nucera, analysts see around 90% upside potential.
ReadCommented by Fabian Lorenz on January 11th, 2024 | 07:00 CET
Evotec is in the analyst check, Tui with Wanderlust, and another 100% gain for Manuka Resources?
The Evotec stock is currently not for the faint-hearted. After the resignation of the long-serving board member caused uncertainty, the biotech company was able to reassure investors with a milestone payment. Analysts are speaking out and expressing their opinions, and a real "bull" is among them. And what about Manuka Resources? At the beginning of December, news about an exciting project for battery metals caused a jump in the share price. Is it now worth getting in after the consolidation? The Tui share has also recently consolidated after a 50% gain within a few weeks. Analysts' price targets for the tourism company's shares vary widely. Hold or buy?
Read